...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Re: Cerebral blood flow in takotsubo syndrome: Is it specific for the disease?
【24h】

Re: Cerebral blood flow in takotsubo syndrome: Is it specific for the disease?

机译：回复：takotsubo综合征中的脑血流：是否对这种疾病有特异性？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

There is accumulating evidence for potential benefits of therapeutic drug monitoring (TDM) in the treatment of cancer with tyrosine kinase inhibitors (TKIs). Relationships between exposure and response (efficacy/toxicity) have been established for several TKIs. For example, the pharmacokinetic targets for efficacy of imatinib, sunitinib and pazopanib have been defined as trough plasma concentrations (C trough) of 1,000, 50 and 20,000 ng/mL for selected indications, respectively. Dose adjustment based on pharmacokinetic targets could therefore increase response rates and duration. Furthermore, with appropriate target concentrations defined, excessive side effects in patients using the current fixed dosing strategy may be prevented. This review provides a practical guideline for TDM for the currently approved TKIs at 28 February 2013. The focus of this article is on the elaboration of exposure and response relationships of TKIs with proposed pharmacokinetic targets, mainly C trough, and further on the interpretation of the pharmacokinetic targets with recommendations for dose titrations.
机译：有越来越多的证据表明，在酪氨酸激酶抑制剂（TKI）的治疗中，治疗药物监测（TDM）的潜在优势。已经针对几种TKI建立了暴露与反应（功效/毒性）之间的关系。例如，伊马替尼，舒尼替尼和帕唑帕尼功效的药代动力学指标已定义为分别针对选定适应症的谷血浆浓度（C谷）分别> 1,000，> 50和> 20,000 ng / mL。因此，根据药代动力学目标进行剂量调整可以提高缓解率和持续时间。此外，通过定义适当的目标浓度，可以防止使用当前固定剂量策略的患者产生过多的副作用。这篇综述为2013年2月28日当前批准的TKI提供了TDM的实用指南。本文的重点是阐述TKI与拟议的药代动力学指标（主要为C谷）的暴露和反应关系，并进一步解释药代动力学目标，并建议剂量滴定。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号